HALIFAX, NS, March 2, 2020
Adaptiiv Medical Technologies Inc. was recently featured in The Chronicle Herald as one of the three companies shaping the medtech startup scene in Atlantic Canada.
Here are some highlights from the article:
Why Adaptiiv is needed
If a patient is receiving radiation therapy for cancer close to the skin’s surface, they often require a so-called bolus.
“It’s a flimsy rubber-like layer that fits over a patient’s skin and allows the radiation to essentially build up dose,” Adaptiiv co-founder and CEO Peter Hickey says. The problem is the bolus doesn’t always fit perfectly. “Patients are all different shapes and sizes,” he says. “If there are air gaps between the bolus and the skin, it can cause radiation to underdose.” In other words, the success of a cancer patient’s treatment can hinge on an ill-fitting piece of rubbery material. That’s where Adaptiiv’s solution comes in.
How Adaptiiv’s solution works
Adaptiiv’s software saves clinicians hours of manual calculations. Health-care workers input data from the patient’s CT scans into the platform, which produces a personalized design. The bolus is then created on a 3D-printer. It’s a cost-effective way to make a custom bolus that fits a patient. This ensures more accurate dosages of radiation therapy in the required areas while sparing healthy tissue.
After securing clearance from the U.S. Food and Drug Administration to market its 3D Bolus Software in 2018, Adaptiiv has rapidly grown its customer base. “We have a significant number of new client announcements that we expect to be rolling out in the coming months,” Hickey says.
Adaptiiv Medical Technologies Inc. is the definitive software platform to design 3D printed medical accessories for use in radiation oncology. Headquartered in Halifax, Nova Scotia, Canada, Adaptiiv is shaping the future of patient-specific healthcare through innovation and collaboration with industry leaders throughout the world. Adaptiiv has FDA 510(k) clearance and has received a CE Mark. The company’s solution is currently used in a clinical setting by clients in 14 countries.